Pfizer Inc. (PFE)
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Why Pfizer (PFE) Dipped More Than Broader Market Today
In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding trading day.
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
Pfizer: I'm Still Expecting A Massive Rebound
Pfizer Inc.'s non-COVID operational revenue grew 9% in Q4, successfully offsetting the ongoing decline in pandemic-related sales and signaling a structural shift toward long-term growth. The Seagen integration has doubled Pfizer's oncology pipeline to 60 programs, with the division on track to hit a $10 billion revenue target by 2030. PFE management anticipates a "steep hockey stick" launch for its obesity portfolio by 2028, targeting a significant share of the projected $200 billion GLP-1 market.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer.
Ameriprise Financial Inc. Increases Holdings in Pfizer Inc. $PFE
Ameriprise Financial Inc. grew its stake in Pfizer Inc. (NYSE: PFE) by 48.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,373,140 shares of the biopharmaceutical company's stock after acquiring an additional 5,978,927 shares during the quarter. Ameriprise Financial Inc. owned
44 Wealth Management LLC Buys Shares of 24,551 Pfizer Inc. $PFE
44 Wealth Management LLC bought a new position in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 24,551 shares of the biopharmaceutical company's stock, valued at approximately $626,000. A number of other institutional investors and
Game Creek Capital LP Trims Stake in Pfizer Inc. $PFE
Game Creek Capital LP cut its holdings in Pfizer Inc. (NYSE: PFE) by 23.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 127,500 shares of the biopharmaceutical company's stock after selling 40,125 shares during the period. Pfizer accounts for 1.1%
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
Pfizer Inc. (PFE) is undervalued at 8–9× forward earnings, offering a nearly 7% dividend yield and significant upside potential. Recent acquisitions, especially Seagen, position PFE for robust growth, with Seagen's revenue projected to exceed $10 billion by 2030. Cost-cutting initiatives and a strong core portfolio support dividend sustainability and margin improvement despite post-COVID revenue declines.
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
Pfizer has been hurt in recent years after the COVID-19 pandemic and recent drug pricing pressure. The stock now trades at a dividend yield of 6.5%.
